Groundbreaking Study: Unlocking Better Prostate Cancer Detection
A recent head-to-head trial has revealed a potential game-changer in the fight against prostate cancer. The Co-PSMA Investigator-Initiated Trial (IIT) has shown that Clarity's diagnostic product, 64Cu-SAR-bisPSMA, is significantly more effective in detecting prostate cancer lesions and patients than the current standard-of-care (SOC), 68Ga-PSMA-11. This discovery could revolutionize the way we approach prostate cancer diagnosis and treatment.
Unlocking the Mystery of Prostate Cancer Recurrence
Abstract Unveiled: The abstract, led by Prof Louise Emmett at St Vincent's Hospital Sydney, has been accepted for oral presentation at the European Association of Urology (EAU) Congress 2026. This prestigious event will showcase the study's key findings to a global audience.
Study Design: The Co-PSMA IIT compared 64Cu-SAR-bisPSMA with 68Ga-PSMA-11 in 50 patients with biochemical recurrence (BCR) of prostate cancer, who had PSA levels between 0.2 and 0.75 ng/mL and were candidates for curative salvage therapy. This direct comparison aimed to assess the diagnostic accuracy and potential benefits of 64Cu-SAR-bisPSMA.
Striking Results: The study revealed that 64Cu-SAR-bisPSMA PET/CT identified a significantly higher number of prostate cancer lesions per patient than 68Ga-PSMA-11 PET/CT. The mean per-patient lesion count was 1.26 for 64Cu-SAR-bisPSMA, compared to 0.48 for 68Ga-PSMA-11, with a difference of 0.78 (95% CI: 0.52 – 1.04) and a ratio of 2.63 (95% CI: 1.64 – 4.20) (p <0.0001). This means 64Cu-SAR-bisPSMA detected more than twice the number of lesions than its counterpart.
Lesion Detection: In total, 68Ga-PSMA-11 identified 24 lesions across all participants, while 64Cu-SAR-bisPSMA next-day imaging detected a remarkable 63 lesions. This difference is crucial, as it could lead to earlier and more accurate treatment decisions.
Patient Detection: At the per-patient level, 68Ga-PSMA-11 identified 36% of trial participants as having a positive scan, while 64Cu-SAR-bisPSMA detected prostate cancer in a staggering 78% of cases. This higher detection rate could significantly impact patient management and outcomes.
Clinical Impact: The study's impact is profound, with 44% of trial participants having their planned patient management changed following the assessment of 64Cu-SAR-bisPSMA PET/CT. This suggests that 64Cu-SAR-bisPSMA could provide valuable insights for clinicians, leading to more effective treatment strategies.
A New Hope for Prostate Cancer Patients
Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, is thrilled to announce these groundbreaking results. The Co-PSMA trial has shown that their product, 64Cu-SAR-bisPSMA, outperforms the current SOC in detecting prostate cancer recurrence. This is particularly significant for patients with low PSA levels, where current SOC PSMA PET agents have limited sensitivity.
Controversy and Innovation: The study's findings are not without controversy. While 64Cu-SAR-bisPSMA has shown remarkable results, it is still an unregistered product. The safety and efficacy have not been assessed by health authorities, and its commercial availability is not guaranteed. But here's where it gets interesting: Clarity's Executive Chairperson, Dr Alan Taylor, highlights the product's potential to become the new SOC in PSMA PET imaging, offering improved diagnosis and treatment for prostate cancer patients.
Building the Evidence: The Co-PSMA trial builds upon previous research, including the COBRA trial, which also demonstrated the superior performance of 64Cu-SAR-bisPSMA in detecting prostate cancer lesions and patients. The COBRA trial showed that 64Cu-SAR-bisPSMA identified more lesions and patients with a positive scan compared to SOC PSMA PET products, including 68Ga-PSMA-11.
Clinical Implications: The implications of these findings are far-reaching. With a higher true positive rate, 64Cu-SAR-bisPSMA enables clinicians to treat prostate cancer with greater confidence and effectiveness. This could lead to earlier interventions, preventing cancer growth and spread, and improving patient outcomes.
Market Potential: The market for PSMA PET imaging is substantial, estimated at US$2 billion per year in the US alone, and expected to grow to over US$3 billion by 2029. However, the current market is dominated by 68Ga-PSMA-11 and 18F-DCFPyL, both with low sensitivity. Clarity believes that 64Cu-SAR-bisPSMA could not only become the new SOC but also expand the market by improving prostate cancer diagnosis at various disease stages.
Expert Insights: Prof Louise Emmett, Principal Investigator in the Co-PSMA trial, emphasizes the need for more sensitive diagnostics in BCR. The study demonstrates that 64Cu-SAR-bisPSMA PET/CT is a significant advancement, offering tailored treatment decisions for patients with recurrent prostate cancer.
Unlocking the Power of SAR-bisPSMA
SAR-bisPSMA is a unique approach, combining two PSMA-targeting agents with Clarity's proprietary sarcophagine (SAR) technology. This technology securely holds copper isotopes, preventing leakage into the body, and can be used for both imaging and therapy.
The Future of Prostate Cancer Care
While 64Cu-SAR-bisPSMA is not yet commercially available, the Co-PSMA trial provides compelling evidence of its potential benefits. The study's acceptance at the EAU Congress 2026 as an oral presentation highlights the importance and impact of these findings.
As we await further data from the Co-PSMA IIT, the question remains: Could 64Cu-SAR-bisPSMA be the key to unlocking better prostate cancer detection and treatment? The answer could revolutionize the field of oncology and significantly improve patient outcomes.
Disclaimer: This article is based on the study's findings and expert opinions. The safety and efficacy of 64Cu-SAR-bisPSMA are yet to be assessed by health authorities, and its commercial availability is not guaranteed.
